Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
16
SAVA Quote, Financials, Valuation and Earnings
Last price:
$2.13
Seasonality move
:
27.11%
Day range:
$2.06 - $2.16
52-week range:
$1.15 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.69x
P/B ratio:
1.24x
Volume:
822.2K
Avg. volume:
1.1M
1-year change:
-27.34%
Market cap:
$101.4M
Revenue:
--
EPS (TTM):
-$2.20
Analysts' Opinion
-
Consensus RatingCassava Sciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.00, Cassava Sciences, Inc. has an estimated upside of 280.95% from its current price of $2.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $2.10.
Fair Value
-
According to the consensus of 1 analyst, Cassava Sciences, Inc. has 280.95% upside to fair value with a price target of $8.00 per share.
SAVA vs. S&P 500
-
Over the past 5 trading days, Cassava Sciences, Inc. has underperformed the S&P 500 by -4.46% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cassava Sciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cassava Sciences, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Cassava Sciences, Inc. reported revenues of --.
Earnings Growth
-
Cassava Sciences, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Cassava Sciences, Inc. reported earnings per share of -$0.22.
Enterprise value:
-4.6M
EV / Invested capital:
--
Price / LTM sales:
2.69x
EV / EBIT:
--
EV / Revenue:
-0.13x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
0.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$880K
Return On Assets:
-67.34%
Net Income Margin (TTM):
--
Return On Equity:
-86.98%
Return On Invested Capital:
-86.98%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$1.6M | -$1.2M | -$880K | -$260K | -$200K | |
| Operating Income | -$104.1M | -$141.6M | -$111.3M | -$31.7M | -$11.9M | |
| EBITDA | -$102.5M | -$140.4M | -$110.4M | -$31.5M | -$11.7M | |
| Diluted EPS | -$2.29 | -$1.37 | -$2.20 | -$0.58 | -$0.22 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $251.9M | $183.3M | $150.2M | $202.5M | $108.9M | |
| Total Assets | $274.2M | $207.3M | $172.5M | $223.8M | $129.7M | |
| Current Liabilities | $6.3M | $8.3M | $17.4M | $57M | $48M | |
| Total Liabilities | $6.7M | $8.6M | $17.4M | $57.1M | $48.2M | |
| Total Equity | $267.6M | $198.7M | $155.1M | $166.6M | $81.6M | |
| Total Debt | $259K | $62K | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$81M | -$78M | -$83.8M | -$18.3M | -$6.2M | |
| Cash From Investing | -$38K | -$87K | -$137K | -$17K | -$80K | |
| Cash From Financing | $48.8M | $124.7M | $1M | -- | -- | |
| Free Cash Flow | -$81.1M | -$78.1M | -$83.9M | -$18.3M | -$6.3M | |
SAVA
Sector
Market Cap
$101.4M
$28.1M
Price % of 52-Week High
42.17%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
-0.72%
-1.55%
1-Year Price Total Return
-27.34%
-19.36%
Beta (5-Year)
-1.000
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.15
200-day SMA
Sell
Level
$2.42
Bollinger Bands (100)
Sell
Level
2.23 - 3.57
Chaikin Money Flow
Sell
Level
-6M
20-day SMA
Sell
Level
$2.65
Relative Strength Index (RSI14)
Sell
Level
35.05
ADX Line
Sell
Level
49.79
Williams %R
Buy
Level
-86.4078
50-day SMA
Sell
Level
$2.95
MACD (12, 26)
Buy
Level
0.56
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-7.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.0499)
Sell
CA Score
(Annual)
Level (-2.9699)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (3.25)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
Stock Forecast FAQ
In the current month, SAVA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SAVA average analyst price target in the past 3 months is $8.00.
-
Where Will Cassava Sciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cassava Sciences, Inc. share price will rise to $8.00 per share over the next 12 months.
-
What Do Analysts Say About Cassava Sciences, Inc.?
Analysts are divided on their view about Cassava Sciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cassava Sciences, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Cassava Sciences, Inc.'s Price Target?
The price target for Cassava Sciences, Inc. over the next 1-year time period is forecast to be $8.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SAVA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cassava Sciences, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of SAVA?
You can purchase shares of Cassava Sciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cassava Sciences, Inc. shares.
-
What Is The Cassava Sciences, Inc. Share Price Today?
Cassava Sciences, Inc. was last trading at $2.13 per share. This represents the most recent stock quote for Cassava Sciences, Inc.. Yesterday, Cassava Sciences, Inc. closed at $2.10 per share.
-
How To Buy Cassava Sciences, Inc. Stock Online?
In order to purchase Cassava Sciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SAVA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SAVA
Sector
P/E ratio
--
24.09x
PEG ratio
-0.02x
-0.01x
P/B ratio
1.24x
1.83x
Price / LTM sales
2.69x
1.59x
Growth Metrics
SAVA
Sector
Revenue growth
--
4.68%
Earnings growth
61.59%
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.68
-$0.18
Profitability
SAVA
Sector
Profitability FY 2024
-$1.1M
$3.6M
Return on invested capital
-86.98%
-31.87%
Return on assets
-67.34%
-28.18%
Return on equity
-86.98%
-37.89%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
9
Estimated Next Earnings Date
Feb
11
Balance Sheet
SAVA
Sector
Total cash
$106.1M
$26.2M
Short term investments
--
$25.7M
Total assets
$157.5M
$76.7M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
